Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965861 · ClinicalTrials.gov registry record
SCRI Tissue Testing Registry
A clinical trial, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- 20
- Enrollment target
NCT00965861: Clinical Trial study, sponsored by SCRI Development Innovations.
NCT00965861 is a clinical trial that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00965861 was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.
Interventions
- OTHER Tissue Registry Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
Why NCT00965861 stopped before completion
NCT00965861 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tissue Registry Study is the first listed.
NCT00965861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00965861 about?
NCT00965861 is a clinical study titled "SCRI Tissue Testing Registry". Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a fut...
What is the current status of trial NCT00965861?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2010-05. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00965861?
The interventions under investigation include: Tissue Registry Study (OTHER).
Who is sponsoring clinical trial NCT00965861?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia